# | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
---|---|---|---|---|---|---|---|---|---|
1. | ALA4194880 | B | Binding affinity to human GCN5L2 expressed in bacterial system assessed as remaining binding level at 1 uM by BROMOscan assay relative to control | Homo sapiens | 3 | ALA4190379 | assay format | Scientific Literature | |
2. | ALA4194881 | B | Binding affinity to human FALZ expressed in bacterial system assessed as remaining binding level at 1 uM by BROMOscan assay relative to control | Homo sapiens | 3 | ALA4190379 | assay format | Scientific Literature | |
3. | ALA4194882 | B | Binding affinity to human TAF1 bromodomain 2 expressed in bacterial system assessed as remaining binding level at 1 uM by BROMOscan assay relative to control | Homo sapiens | 3 | ALA4190379 | assay format | Scientific Literature | |
4. | ALA4194883 | B | Binding affinity to human PBRM1 bromodomain 2 expressed in bacterial system assessed as remaining binding level at 1 uM by BROMOscan assay relative to control | Homo sapiens | 3 | ALA4190379 | assay format | Scientific Literature | |
5. | ALA4194884 | B | Binding affinity to His-tagged BRD4 bromodomain 1 to 2 (K57 to K550 amino acids) (unknown origin) using Alexa647-labeled BET-inhibitor as fluorescent probe by bromodomain TR-FRET binding assay | Homo sapiens | 28 | ALA4190379 | single protein format | Scientific Literature | |
6. | ALA4194885 | F | Antiproliferative activity against human MX1 cells incubated for 72 hrs by cell-titer Glo assay | Homo sapiens | 28 | ALA4190379 | cell-based format | Scientific Literature | |
7. | ALA4194886 | B | Binding affinity to BRD4 in human H1299 cells stably expressing E2 and HPV16-LCR luciferase reporter incubated for 24 hrs by Bright-Glo luciferase reporter gene assay based BRD4 engagement assay | Homo sapiens | 28 | ALA4190379 | cell-based format | Scientific Literature | |
8. | ALA4194887 | A | Intrinsic unbound clearance in human liver microsomes | Homo sapiens | 8 | ALA4190379 | microsome format | Scientific Literature | |
9. | ALA4194888 | A | Intrinsic unbound clearance in mouse liver microsomes | Mus musculus | 8 | ALA4190379 | microsome format | Scientific Literature | |
10. | ALA4194889 | A | Permeability of the compound by PAMPA method | 8 | ALA4190379 | assay format | Scientific Literature | ||
11. | ALA4194890 | A | Unbound clearance in mouse at 10 mg/kg, po | Mus musculus | 8 | ALA4190379 | organism-based format | Scientific Literature | |
12. | ALA4194891 | A | AUC in mouse at 10 mg/kg, po | Mus musculus | 7 | ALA4190379 | organism-based format | Scientific Literature | |
13. | ALA4194893 | A | Oral bioavailability in mouse at 10 mg/kg | Mus musculus | 8 | ALA4190379 | organism-based format | Scientific Literature | |
14. | ALA4194894 | F | Antitumor activity against human OPM2 cells xenografted in SCID-beige mouse assessed as inhibition of tumor growth administered once daily orally for 28 days starting from 18 days post tumor inoculation | Homo sapiens | 2 | ALA4190379 | cell-based format | Scientific Literature | |
15. | ALA4194897 | F | Antitumor activity against human OPM2 cells xenografted in SCID-beige mouse assessed as inhibition of tumor growth at 3.75 mg/kg, po qd administered for 28 days starting from 18 days post tumor inoculation | Homo sapiens | 1 | ALA4190379 | organism-based format | Scientific Literature | |
16. | ALA4194898 | F | Antitumor activity against human OPM2 cells xenografted in SCID-beige mouse assessed as inhibition of tumor growth at 7.5 mg/kg, po qd administered for 28 days starting from 18 days post tumor inoculation | Homo sapiens | 1 | ALA4190379 | organism-based format | Scientific Literature | |
17. | ALA4194901 | T | Toxicity in human OPM2 cells xenografted SCID-beige mouse assessed as body weight loss at 3.75 mg/kg, po qd administered for 28 days starting from 18 days post tumor inoculation | Mus musculus | 1 | ALA4190379 | organism-based format | Scientific Literature | |
18. | ALA4194902 | T | Toxicity in human OPM2 cells xenografted SCID-beige mouse assessed as body weight loss at 7.5 mg/kg, po qd administered for 28 days starting from 18 days post tumor inoculation | Mus musculus | 1 | ALA4190379 | organism-based format | Scientific Literature | |
19. | ALA4194904 | B | Binding affinity to BRD2 bromodomain 1 to 2 (G73 to A560 amino acids) (unknown origin) using Alexa647-labeled BET-inhibitor as fluorescent probe by bromodomain TR-FRET binding assay | Homo sapiens | 3 | ALA4190379 | single protein format | Scientific Literature | |
20. | ALA4194905 | B | Binding affinity to BRD3 bromodomain 1 to 2 (P24 to P416 amino acids) (unknown origin) using Alexa647-labeled BET-inhibitor as fluorescent probe by bromodomain TR-FRET binding assay | Homo sapiens | 3 | ALA4190379 | single protein format | Scientific Literature |